ARIX BIOSCIENCE PLC
Arix Bioscience PLC (ARIX)
Investment team changes
18-Jan-2021 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Investment team changes
LONDON, 18 January 2021: Arix Bioscience plc ("Arix", LSE: ARIX) a global venture capital company focused on investing
and building breakthrough biotech companies, today announces that Jonathan Tobin, PhD, has resigned as Managing
Director to pursue another opportunity. His resignation will be effective from 1 March.
Naseem Amin, MD, Executive Chairman of Arix, commented: "On behalf of the Board and the investment team, I would like
to thank Jonathan for his contribution to the development of Arix since its inception. Our portfolio companies,
particularly where he was the Investment Director, benefited greatly from his counsel and contribution to their
progress. Jonathan departs with our very best wishes. Following a successful 2020, I am confident we have the
investment team to continue management of our current portfolio and source new opportunities. We will be expanding our
investment team both in the US and London as we continue to deploy capital into new opportunities."
Jonathan Tobin, PhD, added: "It has been an honour to work with such a high quality team and portfolio of innovative
companies, led by some of the most successful scientists and entrepreneurs in biotech. Arix has grown significantly
since its inception and built a broad portfolio of companies, each with the potential to bring important breakthrough
therapies to patients. These companies are expected to reach significant clinical milestones in the near and medium
term and all have potential to generate substantial value for Arix shareholders."
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Supriya Mathur, Shabnam Bashir, Manel Mateus
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech
companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate
their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth
phase of our industry to a broader range of investors. www.arixbioscience.com
=----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCH
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 91645
EQS News ID: 1161160
End of Announcement EQS News Service
=------------------------------------------------------------- (MORE TO FOLLOW) Dow Jones Newswires
January 18, 2021 02:00 ET (07:00 GMT)
